Aristides Capital’s Cabaletta Bio CABA Stock Holding History

Aristides Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75,400	Closed	-$171K	–	246
2024 Q4	$171K	Buy	+75,400	New	+$265K	0.04%	263

Other funds holding CABA

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's CABA Position: Q1 2025 in Review

Aristides Capital sold out of Cabaletta Bio (CABA) in Q1 2025, closing a stake of 75,400 shares — an estimated $171K sold.

Aristides Capital first reported a position in CABA in Q4 2024 and held it in 1 quarter. The position peaked at $171K in Q4 2024. 92 funds tracked by Wall St. Rank hold CABA as of Q1 2025.

Aristides Capital reported no remaining Cabaletta Bio position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 75,400 Cabaletta Bio shares in Q1 2025, an estimated $171K.
Aristides Capital first reported a position in Cabaletta Bio in Q4 2024 and held it in 1 quarter.
Aristides Capital's Cabaletta Bio position peaked at $171K in Q4 2024.
92 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.